The combination of BET and METTL3 inhibitors elicits synergistic antitumor effects in ovarian cancer cells via reducing SP1 and BCL-2 expression
DOI:
10.1016/j.lfs.2025.123505
Publication Date:
2025-02-25T23:54:01Z
AUTHORS (9)
ABSTRACT
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (57)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....